Showing 241 - 260 results of 6,805 for search '(( significantly ((less decrease) OR (we decrease)) ) OR ( significantly weaker decrease ))', query time: 0.61s Refine Results
  1. 241

    Contains R code utilized in the analyses. by Arttu Autio-Kimura (20454681)

    Published 2024
    “…Spearman correlation analysis between the individuals’ calendar ages and cell type proportions revealed a statistically significant decrease in the proportion of neurons with increasing age. …”
  2. 242

    Data for the G7 countries in 2022. by Luis Alberiko Gil-Alana (14659817)

    Published 2024
    “…The results indicate that only France displays a significant negative trend and thus a continuous decrease in the level of alcohol consumption. …”
  3. 243

    Time series plots: Alcohol consumption. by Luis Alberiko Gil-Alana (14659817)

    Published 2024
    “…The results indicate that only France displays a significant negative trend and thus a continuous decrease in the level of alcohol consumption. …”
  4. 244

    Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    “…While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …”
  5. 245
  6. 246
  7. 247
  8. 248
  9. 249
  10. 250

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  11. 251

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  12. 252

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  13. 253

    Demethylation Pathway of Methylmercury in the Spleen and Peripheral Organs of Bluefin TunaImplications for Fish Consumers by Alain Manceau (1455781)

    Published 2025
    “…While the spleen is well-known as the body’s largest immune organ, its role in detoxification is less recognized. Here, we used high-energy-resolution X-ray absorption spectroscopy to examine the chemical forms of mercury (Hg) in ABFT tissues, building on prior analysis of stable Hg isotopes. …”
  14. 254
  15. 255

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  16. 256

    MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

    Published 2025
    “…2D MXene nanosheets often encounter challenges such as aggregation and restacking, which can significantly decrease their performance in supercapacitor applications. …”
  17. 257
  18. 258
  19. 259
  20. 260